Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 9Urinary Bladder Neoplasms 4Urethral Neoplasms 4Melanoma 4Sarcoma 3Prostatic Neoplasms 3Ovarian Neoplasms 3Osteosarcoma 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3Carcinoma, Hepatocellular 3Urogenital Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Penile Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Lung Neoplasms 2HIV Infections 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Digestive System Neuroendocrine Tumor G1 × cabozantinib × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡